[{"id":"d370580d-08ca-46be-ad4d-fa3e345e72eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05758610","created_at":"2023-03-07T18:03:06.860Z","updated_at":"2024-07-02T16:35:04.889Z","phase":"Phase 1","brief_title":"A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients","source_id_and_acronym":"NCT05758610","lead_sponsor":"Shengke Pharmaceuticals (Jiangsu) Limited, China","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ETH-155008"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/04/2022","start_date":" 11/04/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-08"},{"id":"3595892a-b438-47a6-9905-bb90d4dc044d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02078609","created_at":"2021-01-18T09:34:53.711Z","updated_at":"2024-07-02T16:36:37.178Z","phase":"Phase 1","brief_title":"A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT02078609","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • EIF4EBP1","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 wild-type","tags":["FLT3 • EIF4EBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • PIM447"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 03/20/2014","start_date":" 03/20/2014","primary_txt":" Primary completion: 04/18/2019","primary_completion_date":" 04/18/2019","study_txt":" Completion: 04/18/2019","study_completion_date":" 04/18/2019","last_update_posted":"2020-12-17"},{"id":"8c1986b9-dc33-4fc4-9d2c-4142d27461c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02144038","created_at":"2021-01-18T09:57:37.462Z","updated_at":"2024-07-02T16:36:37.224Z","phase":"Phase 1","brief_title":"Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma","source_id_and_acronym":"NCT02144038","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EIF4EBP1","pipe":"","alterations":" ","tags":["EIF4EBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • PIM447"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 07/23/2014","start_date":" 07/23/2014","primary_txt":" Primary completion: 10/28/2015","primary_completion_date":" 10/28/2015","study_txt":" Completion: 10/28/2015","study_completion_date":" 10/28/2015","last_update_posted":"2020-12-17"}]